Bioventix PLC
BVXP
Company Profile
Business description
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
Contact
27-28 Eastcastle Street
LondonW1W 8DH
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
16
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Which of the 3 giant AI IPOs should you buy?
OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.90 | 124.80 | -1.40% |
| CAC 40 | 7,962.39 | 0.00 | 0.00% |
| DAX 40 | 23,168.08 | 130.81 | -0.56% |
| Dow JONES (US) | 46,504.67 | 61.07 | -0.13% |
| FTSE 100 | 10,436.29 | 71.50 | 0.69% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,879.18 | 38.23 | 0.18% |
| Nikkei 225 | 53,123.49 | 616.19 | -1.15% |
| NZX 50 Index | 12,902.15 | 76.28 | 0.59% |
| S&P 500 | 6,582.69 | 7.37 | 0.11% |
| S&P/ASX 200 | 8,579.50 | 105.50 | -1.21% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |